Literature DB >> 29530654

Safety of a Brief Emergency Department Observation Protocol for Patients With Presumed Fentanyl Overdose.

Frank X Scheuermeyer1, Christopher DeWitt2, Jim Christenson2, Brian Grunau2, Andrew Kestler2, Eric Grafstein2, Jane Buxton3, David Barbic2, Stefan Milanovic2, Reza Torkjari2, Indy Sahota2, Grant Innes4.   

Abstract

STUDY
OBJECTIVE: Fentanyl overdoses are increasing and few data guide emergency department (ED) management. We evaluate the safety of an ED protocol for patients with presumed fentanyl overdose.
METHODS: At an urban ED, we used administrative data and explicit chart review to identify and describe consecutive patients with uncomplicated presumed fentanyl overdose (no concurrent acute medical issues) from September to December 2016. We linked regional ED and provincial vital statistics databases to ascertain admissions, revisits, and mortality. Primary outcome was a composite of admission and death within 24 hours. Other outcomes included treatment with additional ED naloxone, development of a new medical issue while in the ED, and length of stay. A prespecified subgroup analysis assessed low-risk patients with normal triage vital signs.
RESULTS: There were 1,009 uncomplicated presumed fentanyl overdose, mainly by injection. Median age was 34 years, 85% were men, and 82% received out-of-hospital naloxone. One patient was hospitalized and one discharged patient died within 24 hours (combined outcome 0.2%; 95% confidence interval [CI] 0.04% to 0.8%). Sixteen patients received additional ED naloxone (1.6%; 95% CI 1.0% to 2.6%), none developed a new medical issue (0%; 95% CI 0% to 0.5%), and median length of stay was 173 minutes (interquartile range 101 to 267). For 752 low-risk patients, no patients were admitted or developed a new issue, and one died postdischarge; 3 (0.4%; 95% CI 0.01% to 1.3%) received ED naloxone.
CONCLUSION: In our cohort of ED patients with uncomplicated presumed fentanyl overdose-typically after injection-deterioration, admission, mortality, and postdischarge complications appear low; the majority can be discharged after brief observation. Patients with normal triage vital signs are unlikely to require ED naloxone.
Copyright © 2018 American College of Emergency Physicians. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29530654     DOI: 10.1016/j.annemergmed.2018.01.054

Source DB:  PubMed          Journal:  Ann Emerg Med        ISSN: 0196-0644            Impact factor:   5.721


  7 in total

1.  Emergency Department Initiation of Buprenorphine for Opioid Use Disorder: Current Status, and Future Potential.

Authors:  Lindsay Fox; Lewis S Nelson
Journal:  CNS Drugs       Date:  2019-12       Impact factor: 5.749

2.  Overdose Research: 15 Years Later.

Authors:  Phillip O Coffin; Josiah D Rich
Journal:  J Urban Health       Date:  2019-02       Impact factor: 3.671

3.  Emergency Department Visits for Opioid Overdoses Among Patients With Cancer.

Authors:  Vikram Jairam; Daniel X Yang; James B Yu; Henry S Park
Journal:  J Natl Cancer Inst       Date:  2020-09-01       Impact factor: 13.506

4.  Naloxone Dosing After Opioid Overdose in the Era of Illicitly Manufactured Fentanyl.

Authors:  Joseph Carpenter; Brian Patrick Murray; Sukhshant Atti; Tim P Moran; Arthur Yancey; Brent Morgan
Journal:  J Med Toxicol       Date:  2019-08-30

5.  Observation unit management of low-risk emergency department patients with acute drug overdose.

Authors:  Siri Shastry; Jonathan Yeo; Lynne D Richardson; Alex F Manini
Journal:  Clin Toxicol (Phila)       Date:  2019-09-25       Impact factor: 4.467

Review 6.  Treatment of opioid overdose: current approaches and recent advances.

Authors:  Stevie C Britch; Sharon L Walsh
Journal:  Psychopharmacology (Berl)       Date:  2022-04-07       Impact factor: 4.530

Review 7.  The rising crisis of illicit fentanyl use, overdose, and potential therapeutic strategies.

Authors:  Ying Han; Wei Yan; Yongbo Zheng; Muhammad Zahid Khan; Kai Yuan; Lin Lu
Journal:  Transl Psychiatry       Date:  2019-11-11       Impact factor: 6.222

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.